Biotechnology News and Research

RSS

Microbial Pathogenomics: A collection of reviews and future trends in bacterial pathogenomics

'Microbial Pathogenomics' contains a unique collection of reviews demonstrating how genomics has revolutionized our understanding of virulence, host-adaptation strategies and the evolution of bacterial pathogens. Current technologies - computational tools and functional approaches to genome analysis - are carefully documented and clearly illustrated.

23 Dec 2009

Researchers develop new approach for treating and healing skin abscesses

Researchers at the Albert Einstein College of Medicine of Yeshiva University have developed a new approach for treating and healing skin abscesses caused by bacteria resistant to most antibiotics.

23 Dec 2009

US Oncology to host webinar to discover how new legislation will impact cancer care in 2010

Federal legislation on health care reform and coverage expansion will have major impacts on cancer care. Community oncology professionals need to know how this legislation impacts them and their community practice. US Oncology, Inc., supporting the nation's foremost cancer treatment and research network, announced today that it will host a complimentary educational webinar for community-based oncology practices to discover how this new legislation will impact cancer care in 2010.

23 Dec 2009

US Phase 2 clinical trial of RVX-208 commenced by Resverlogix

Resverlogix Corp. ("Resverlogix" or the "Company") announced today that it has begun dosing patients in its US Phase 2 clinical trial lead by Cleveland Clinic. This trial will examine RVX-208, Resverlogix's oral small molecule therapy for the treatment of atherosclerosis, in patients with stable coronary artery disease (CAD).

23 Dec 2009

Amgen and Roche end EPO patent infringement dispute

Amgen announced today that the United States (U.S.) District Court in Boston has entered final judgment and a permanent injunction against Roche prohibiting Roche from infringing Amgen's patents on recombinant erythropoietin (EPO), thus bringing the five-year patent infringement dispute to an end.

23 Dec 2009

Viron Therapeutics' three drug candidates granted U.S. patents

Viron Therapeutics Inc., a biotechnology company pioneering the development of virally-derived protein therapeutics, today announced that it has been granted U.S. patents related to three of its drug candidates, VT-111, VT-346 and VT-384.

23 Dec 2009

WuXi PharmaTech announces winners of third Life Science and Chemistry Awards

WuXi PharmaTech, a leading pharmaceutical, biotechnology, and medical-device research and development outsourcing company with operations in China and the United States, today announced the winners of its third Life Science and Chemistry Awards, held on December 20, 2009, at the China World Hotel in Beijing.

23 Dec 2009

Guardian Technologies International meets and presents SM TBDx to Indian healthcare officials

Tuberculosis (TB) continues to be a serious global pandemic health threat with more than 9 million new cases diagnosed annually. TB is a leading cause of mortality in India, killing nearly 1,000 people each day.

23 Dec 2009

OSI Pharmaceuticals provides update to ODAC meeting

OSI Pharmaceuticals, Inc. today provided an update to the preliminary revenue and adjusted earnings per share growth rate guidance provided to investors at the Company’s recent analyst R&D day meeting on December 3, 2009. The Company now believes that the 2010 overall revenue percentage growth rate will be in the mid-teens and re-affirms that adjusted earnings per share will grow at 10% or more.

22 Dec 2009

Arrayit achieves technological breakthrough in microarray production

Arrayit Corporation, a life sciences and healthcare technology leader, today announced that the Company has made a technological breakthrough in the speed and efficiency by which it manufactures its proprietary microarrays, which are tiny glass substrates that contain rows and columns of printed spots used for scientific research and molecular diagnostics.

22 Dec 2009

Viral Genetics files updated Information Statement at www.pinksheets.com

Biotechnology company Viral Genetics today announced that it filed an updated Information Statement including unaudited consolidated financial statements for the nine months ended September 30, 2009, as well as year-end statements for December 31, 2008 and 2007.

22 Dec 2009

Veolia Energy North America and Morgan Stanley Infrastructure Partners to acquire MATEP for $320 million

...

22 Dec 2009

WuXi PharmaTech chosen for the Deloitte Technology Fast 500 Asia Pacific 2009 List

WuXi PharmaTech, a leading pharmaceutical, biotechnology, and medical-device research and development outsourcing company, with operations in China and the United States, announced that it had been selected for the Deloitte Technology Fast 500 Asia Pacific 2009 List, the only company in China to receive this award for the past six years. The Deloitte program recognizes technology companies in the Asia Pacific region that have achieved the highest rates of revenue growth during the preceding three years.

22 Dec 2009

Cell Therapeutics supports Code on Interactions with Healthcare Professionals

Cell Therapeutics, Inc. announced today its support of the Pharmaceutical Research Manufacturers of America's (PhRMA) "Code on Interactions with Healthcare Professionals, revised July 2008" (PhRMA Code). Adherence to the Code is voluntary for commercial biotechnology and pharmaceutical companies.

22 Dec 2009

Paul Capital Healthcare leads investment to provide more than $100 million to UCB S.A.

Paul Capital Healthcare today announced that it has led an investment to provide more than $100 million to UCB S.A. in exchange for certain payments relating to the sales of products marketed by third parties. The underlying third party products (which are non-core to UCB) are leading brands in their therapeutic fields.

22 Dec 2009

Bioheart makes breakthrough in stem cell treatment for critical limb ischemia

Bioheart, Inc. offers yet another medical breakthrough with the next-level stem cell treatment for critical limb ischemia patients. The stem cells aid in promoting angiogenesis or the formation of new blood vessels and providing support for the healing of damaged blood vessels.

22 Dec 2009

Complete Response letter related to the BLA for azficel-T offered to Fibrocell Science

Fibrocell Science, Inc. announced today that it has received a Complete Response letter from the U.S. Food and Drug Administration (FDA) related to the Biologics License Application (BLA) for azficel-T, an autologous cell therapy for the treatment of moderate to severe nasolabial fold wrinkles in adults.

22 Dec 2009

FDA extends action date for its review of Cephalon's sNDA for NUVIGIL Tablets

Cephalon, Inc. today announced that the U.S. Food and Drug Administration (FDA) has extended the action date to March 29, 2010, for its review of the supplemental New Drug Application (sNDA) for NUVIGIL® (armodafinil) Tablets [C-IV].

22 Dec 2009

Bioject Medical Technologies completes a Series G Preferred Stock financing

Bioject Medical Technologies Inc., a leading developer of needle-free injection therapy systems, today announced that on December 18, 2009, it completed a Series G Preferred Stock financing with each of Life Sciences Opportunities Fund II, L.P., Life Sciences Opportunities Fund (Institutional) II, L.P. (collectively, the “LOF”), and Edward Flynn for the purchase of an aggregate of 92,448 shares of its Series G Convertible Preferred Stock at a price of $13.00 per share.

21 Dec 2009

TessArae's RM-Flu test granted FDA EUA

TessArae, LLC, a privately held company, and Affymetrix Inc., (NASDAQ:AFFX) today announced that the Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) to TessArae for its TessArray® Resequencing Influenza A Microarray Detection Panel for the Detection of the 2009 H1N1 Influenza A Virus (TessArray RM-Flu test) for the duration of the declaration of emergency unless revoked earlier. The declaration of emergency will expire on April 26, 2010, unless terminated earlier or renewed.

21 Dec 2009